High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma
cells, either by killing the cells or by stopping them from dividing. Having a peripheral
stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows
higher doses of chemotherapy to be given so that more plasma cells are killed. By reducing
the number of plasma cells, the disease may progress more slowly.
PURPOSE: This phase II trial is studying how well giving high-dose melphalan together with
peripheral stem cell transplant works in treating patients with primary amyloidosis or
amyloidosis associated with multiple myeloma.